



ASX ANNOUNCEMENT

4 May 2017

Cynata Presentation and Webcast

Melbourne, Australia; 4 May 2017: Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), has today released a webcast recording with Cynata Managing Director and Chief Executive Officer Dr Ross Macdonald and FUJIFILM Corporate Vice President and General Manager, Regenerative Medicine Business Division, Mr Toshi Ban. The webcast provides investors and media with a deeper understanding of Cynata's investment case, business strategy and strategic relationship with FUJIFILM.

In this webcast, Dr Macdonald discusses:

- The Company's unique and highly valuable therapeutic mesenchymal stem cell (MSC) technology;
- Development progress and target therapeutic areas;
- The strategic relationship with FUJIFILM and the next steps in that partnership; and
- Cynata's business model

Mr Ban provides an overview of FUJIFILM's strategy in the regenerative medicine field and therapeutic stem cells, the importance of Cynata in that strategy and the fit between FUJIFILM's 2015 acquisition of Cellular Dynamics International, Inc and the partnership with Cynata.

To listen to the webcast please click here: <http://cynata.com/news/webcast-recording-with-dr-ross-macdonald/>

Ends

CONTACTS: Dr Ross Macdonald, CEO: Tel: 0412 119343; email ross.macdonald@cynata.com
Andrew Ramadge, Australia Media Contact, 0475 797 471, andrew.ramadge@mcpartners.com.au

About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical stage stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus™ technology addresses a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus™ utilises induced pluripotent stem cells (iPSCs) to produce a particular type of MSC precursor, called a mesenchymoangioblast (MCA). The Cymerus™ platform provides a source of MSCs that is independent of donor limitations and provides an "off-the-shelf" stem cell platform for therapeutic product use, with a pharmaceutical product business model and economies of scale. This has the potential to create a new standard in the emergent arena of stem cell therapeutics and provides both a unique differentiator and an important competitive position.